ArticleJournal of Korean medical science2024
Letter to the Editor: Commentary on "Bevacizumab Alone Versus Bevacizumab Plus Irinotecan in Patients With Recurrent Glioblastoma".
Paolo TiniPubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.